Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 3,649–3,656 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Roche Holding AG ADR TECENTRIQ (atezolizumab) - (IMmotion010) Renal Cell Carcinoma Phase 3 Intravenous Oncology
Roche Holding AG ADR TECENTRIQ (atezolizumab) - (IMpower030) Non-small cell lung cancer (NSCLC) Phase 3 Ongoing Intravenous Oncology
Roche Holding AG ADR TECENTRIQ (atezolizumab) - (IMbrave050) Hepatocellular carcinoma Phase 3 Intravenous Oncology
Roche Holding AG ADR Crenezumab - (CREAD 2) Alzheimer’s disease Phase 3 Trial Discontinued Intravenous Neurology
Roche Holding AG ADR VENCLEXTA (venetoclax) - (CANOVA) Multiple Myeloma Phase 3 Oral Oncology
Roche Holding AG ADR Crenezumab - (CREAD 1) Alzheimer’s disease Phase 3 Trial Discontinued Intravenous Neurology
Roche Holding AG ADR TECENTRIQ (atezolizumab) - (IMvoke010) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 3 Intravenous Oncology
Roche Holding AG ADR Faricimab (RG7716) Neovascular age related macular degeneration (nAMD) Phase 3 Intravitreal Opthalmic